For patients with anaplastic thyroid carcinoma harboring the BRAF V600E mutation, the combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) provides an important targeted option, dramatically improving outcomes in a disease that previously had a dismal prognosis [134,135]. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.